ICM

Edison issues update on UIL (UTL): Long-term focus, avoiding short-term noise

Retrieved on: 
Wednesday, March 13, 2024

Edison issues update on UIL (UTL): Long-term focus, avoiding short-term noise

Key Points: 
  • Edison issues update on UIL (UTL): Long-term focus, avoiding short-term noise
    The issuer is solely responsible for the content of this announcement.
  • Edison issues update on UIL (UTL): Long-term focus, avoiding short-term noise
    UIL Limited (UIL) is managed by Charles Jillings and his highly experienced team at value-based specialist investor ICM.
  • It is a unique portfolio of undervalued assets, which is illustrated by the fund’s differentiated exposures.
  • The majority of the portfolio, around 75%, is held in platforms (collective investment companies), with the balance in direct investments.

Interlink Electronics, Inc. Presenting and Exhibiting at LOPEC 2024 - the world's leading exhibition and conference for flexible, organic, and printed electronics

Retrieved on: 
Thursday, February 29, 2024

IRVINE, Calif., Feb. 29, 2024 /PRNewswire/ -- Interlink Electronics, Inc. (Nasdaq: LINK) is pleased to announce that it will present and exhibit at LOPEC 2024 at the ICM in Munich, Germany, on the 6th and 7th of March. LOPEC is the world's leading exhibition and conference for flexible, organic, and printed electronics. As a global provider of sensors and printed electronic solutions, we are pleased to be in Munich to demonstrate that we are a leading player in the printed electronics value chain. Every year in Munich, the leading industry players come together to share their innovations and drive the development of the next generation of materials, equipment and applications of flexible printed electronics.

Key Points: 
  • LOPEC is the world's leading exhibition and conference for flexible, organic, and printed electronics.
  • As a global provider of sensors and printed electronic solutions, we are pleased to be in Munich to demonstrate that we are a leading player in the printed electronics value chain.
  • Interlink has successfully developed and supplied our printed force and piezoelectric sensor solutions to leading OEMs and electronics companies for nearly 40 years.
  • "We have a proven track record of successful innovation and commercialization in printed electronics.

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

Retrieved on: 
Wednesday, February 7, 2024

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care.
  • “As a leader in AI-powered stroke detection and care coordination, Viz.ai does not rest on what we have done, but instead continues to invest in proving the accuracy and impact of our comprehensive Viz Neuro Suite,” said Molly Madziva Taitt, VP, Global Clinical Affairs.
  • This study is the first of its kind to assess the impact of AI in the acute stroke workflow based on user engagement.
  • For more information on the Viz Neuro Suite, visit https://www.viz.ai/neuro .

Tideline and Impact Capital Managers Publish Research on Cutting Edge Approaches to Investor Value Creation, Showing How Impact Can Drive Financial Outperformance

Retrieved on: 
Wednesday, February 7, 2024

NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Impact Capital Managers (ICM) and Tideline today published new research that explores how a committed approach to impact value creation can drive both financial and impact performance. This report is the latest in the "Alpha in Impact" series, which was launched by ICM in 2018 to explore the various ways in which impact objectives enhance financial value for investors throughout the investment management lifecycle. The full report, "New Frontiers in Value Creation," is available at https://tideline.com/NewFrontiersinValueCreation

Key Points: 
  • NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Impact Capital Managers (ICM) and Tideline today published new research that explores how a committed approach to impact value creation can drive both financial and impact performance.
  • This commitment to impact efficacy is often pursued by investors with the goal of driving a commensurate improvement in the financial return of their investments.
  • Not only do we show that an impact edge can enhance financial performance, but we reveal the proven strategies impact investors are using to achieve those impact and financial performance uplifts."
  • The second "Alpha in Impact" report – also published with Morrison Foerster and released in 2023 – was titled " Strengthening Outcomes: Impact and Financial Value at Exit ."

MEDITWIN Brings Together French Science and Technology Excellence Around Virtual Twins for the Future of Medical Care

Retrieved on: 
Wednesday, January 24, 2024

MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.

Key Points: 
  • MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.
  • The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment.
  • Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology.
  • The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare.

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Retrieved on: 
Wednesday, December 20, 2023

Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.

Key Points: 
  • Additionally, the company shared updated strategic priorities aimed at further optimizing its portfolio for the treatment of neurodegenerative conditions.
  • "We are proud to announce initial clinical data from our upliFT-D clinical trial, which showcases the ability of PBFT02 to elevate CSF progranulin to supraphysiologic levels at the lowest tested dose, Dose 1, up to six months post-treatment.
  • The upliFT-D clinical trial evaluates PBFT02 as a single dose delivered via intra-cisterna magna (ICM) injection.
  • These strategic priorities and clinical milestones underscore Passage Bio's dedication to advancing cutting-edge, one-time genetic medicines and protecting patients and families against loss in neurodegenerative conditions.

UpHealth Provides Corporate Update And Issues Financial Results For The Third Quarter Of 2023

Retrieved on: 
Monday, November 20, 2023

DELRAY BEACH, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“we,” “UpHealth,” or the “Company”) (NYSE: UPH), today issued a corporate update in the form of a letter to shareholders on behalf of CEO, Martin Beck, inclusive of financial results for the third quarter ended September 30, 2023.

Key Points: 
  • For the third quarter of 2023, we reported total revenues of $32.7 million, compared to $38.7 million in the third quarter of 2022.
  • Our gross margin expanded to 54% in the third quarter of 2023, up from 44% in the third quarter of 2022.
  • Due to the deconsolidation of UpHealth Holdings, this excludes approximately $35.6 million of cash at UpHealth Holdings as of September 30, 2023.
  • On September 19, 2023, UpHealth Holdings, a subsidiary of UpHealth, filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code.

Lincolnland achieves production goals and value creation after APP™ installation.

Retrieved on: 
Monday, December 18, 2023

Lincolnland Agri-Energy, a biorefinery based in eastern Illinois, has been producing high-protein feed with the APP™ since August.

Key Points: 
  • Lincolnland Agri-Energy, a biorefinery based in eastern Illinois, has been producing high-protein feed with the APP™ since August.
  • ICM’s stepwise approach to process design allowed Lincolnland to integrate additional technologies required to produce high-protein animal feed.
  • “We are very pleased with how the APP™ integrated with our facility,” said Eric Mosbey, general manager at Lincolnland.
  • With the APP™, Lincolnland can produce up to 5.5 pounds of high-protein feed per bushel of corn.

Modalis and JCR Pharmaceuticals enter into joint research agreement

Retrieved on: 
Tuesday, December 12, 2023

Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) today announced that it has entered into a joint research agreement with JCR Pharmaceuticals Co., Ltd. (JCR Pharmaceuticals) on joint evaluation of the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target.

Key Points: 
  • Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) today announced that it has entered into a joint research agreement with JCR Pharmaceuticals Co., Ltd. (JCR Pharmaceuticals) on joint evaluation of the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target.
  • Taking this agreement as an opportunity, Modalis and JCR Pharmaceuticals aim to establish the new gene therapies for undisclosed CNS diseases by applying J-Brain Cargo®, JCR Pharmaceuticals’ proprietary technology for crossing the blood-brain barrier (BBB), and CRISPR-GNDM® (Guide Nucleotide-Directed Modulation), Modalis proprietary epigenome modulation technology which does not require DNA cleavage.
  • Therefore, this joint research is an important step to explore the application of J-Brain Cargo®, with the aim of establishing new gene therapies in combination with CRISPR-GNDM®.
  • Haru Morita, CEO of Modalis, stated: “JCR Pharmaceuticals’ proprietary BBB penetrating technology, J-Brain Cargo®, has successfully and efficiently delivered biopharmaceutical candidates of various modalities to the CNS.

VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore

Retrieved on: 
Monday, December 11, 2023

VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners.

Key Points: 
  • VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners.
  • VINSSEN signed a contract with Shell in 2022 to supply the hydrogen fuel cell for the project.
  • The main components of the hydrogen fuel cell system delivered by VINSSEN comprise Fuel Cell Module (FCM), Integrated Converter Module (ICM), Lithium-Ion Battery (LIB), and Transformer (TR) for vessel auxiliary power generation.
  • VINSSEN plans to deploy manpower directly to the Singapore shipyard to install, integrate, and inspect the hydrogen fuel cell system.